Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of AFP producing gastric carcinoma with liver metastasis that showed marked response to combined chemotherapy with UFT and Adriamycin (ADM) is reported. A 61-year-old man was admitted because of lassitude and abdominal fullness. An upper GI series and computed tomography revealed gastric cancer (Borrmann III) and multiple liver tumors. He had a remarkably high serum AFP level (90,000 ng/ml) and a high CEA level (270 ng/ml). The presence of AFP in the tumor cells of the biopsy specimen was proved immunohistochemically. He was treated with 600 mg of UFT orally every day and ADM (10 mg, iv, on days 1-4, repeated every 14 days), resulting in marked regression (PR, partial response) of both the primary tumor and liver metastasis on the 33 rd day after the start of treatment, with decreasing of serum levels of AFP and CEA. The patient has been asymptomatic without evidence of recurrence for a follow-up period of more than three months with continuing treatment in our outpatient clinic. UFT-ADM therapy appears to be useful for gastric cancer.
 ...
PMID:[Alpha-fetoprotein producing gastric cancer responding to combined chemotherapy with UFT and adriamycin]. 243 Jan 21

Serum AFP levels were increased in 17 of 446 patients with primary gastric cancer, No liver metastasis was detected in 11 of them. In all patients who underwent gastrectomy, the post-operative AFP levels were significantly lowered. In patients with recurrence, the increase of AFP levels was detected before the diagnosis of recurrent tumor could be achieved by US or CT. The tumor invasion in most of these patients was graded as ss. Lymph node metastasis was found in all patients. Most tumors were histologically classified as tub 2. The histochemical demonstration of AFP in carcinoma cells of the stomach and metastatic lesions of the liver suggests tht AFP may be produced within cancer cells. The prognosis was generally poor.
 ...
PMID:[AFP-producing gastric cancer--analyses of 17 cases]. 243 72

In 117 patients with colorectal cancer, the serum levels of CEA, TPA, CA 19-9, IAP, and, AFP have been compared with the clinical findings. The combined assay of 5 tumor markers were found to be useful for the screening of colorectal cancer. Excluding the AFP, positive rate of the markers for colorectal cancer was higher than that for breast cancer (p less than 0.01) and similar to that for gastric cancer. The serum levels of TPA, CEA and CA 19-9 correlated with the histological progression. Thus, they may be an indicator of the degree of lymph node metastasis, liver metastasis, the histological depth, and also may be useful in evaluating the prognosis of patients with colorectal cancer.
 ...
PMID:[Clinical evaluation of tumor markers in patients with colorectal cancer]. 244 27

Microfluorometric analysis of DNA content was performed on samples from 172 gastrectomy specimens of cancer. Histograms of DNA content were classified into three ploidy patterns; type I, II and III. Also, immunocytochemical examination for tumor markers (CEA, AFP and hCG) was performed. Type I was predominant in intramucosal carcinoma. Type III was predominant in differentiated carcinomas, in elevated type of early carcinomas and in gross type 1 and 2 of advanced carcinomas. Prognostic serosal factor exerted a greater influence on the prognosis than ploidy pattern. But in the patient without prognostic serosal factor, type III had a poorer prognosis than the other types because of vessel invasion, lymph node metastasis and liver metastasis. AFP and hCG were highly positive in type III. Furthermore type III cancer producing more than two tumor markers had an extremely poor prognosis. Analysis of ploidy pattern and tumor markers may prove to be a highly useful adjunct in the evaluation of malignancy in gastric cancer.
 ...
PMID:[Malignancy of gastric cancer according to DNA ploidy pattern and tumor markers]. 244 78

A 48-year-old male developed gastric cancer (Borrmann III) with lung and liver metastases. Laboratory examination revealed a markedly elevated AFP (24, 241 ng/ml), CEA (9739.8 ng/ml), and CA-19-9 (726U/ml). Nevertheless, he underwent a subtotal gastrectomy for the hemostasis of a bleeding malignant lesion. Histological examination showed a moderately differentiated adenocarcinoma. A PAP for an AFP and a CEA disclosed positive staining. In addition, An autopsy revealed metastases to the liver and lungs with a positive result of PAP for AFP and CEA. Further, CA19-9 also was confirmed weakly in these same tissues, histochemically. Therefore this gastric cancer was considered an AFP, CEA, and CA19-9-producing tumor. Gastric cancer with 3 elevated tumor markers in the same patient is rare and its mechanism may elucidate the origin of gastric cancer and the resulting differentiation in the foregut.
 ...
PMID:[An autopsy case of a gastric cancer associated with elevated AFP, CEA and CA19-9]. 245 Feb 14

We have studied the effect of an anti-FP antibody coupled via a dextran bridge to adriamycin on six AFP-producing liver tumors (3 cases with hepatoma and 3 cases with liver metastases from an AFP-producing gastric cancer). Results have revealed that MR was observed in 2 out the 5 of surviving evaluated cases. The toxicity of this conjugate was not evident in all cases, except for a low-grade fever. Further, an autopsy revealed no remarkable change in the histology of the case that had ended in death. These results indicate that this conjugate can be considered one of the treatment therapies available for a nonresectable AFP-producing tumor.
 ...
PMID:[Effect of a conjugate of adriamycin and an antibody to human alpha-fetoprotein (AFP) on AFP-producing hepatic tumors]. 245 9

A case of an AFP-producing gastric cancer accompanied with non-epithelial tumor is reported. A 63-year-old man, complaining of an epigastric hunger pain, was admitted to our hospital. Testing revealed that he had an extremely high level serum AFP (12,400 ng/ml) with no abnormality of liver function. A barium ingestion and a subsequent endoscopic examination determined the existence of a Borrmann III type advanced gastric cancer on the lesser curvature, extending from middle corpus to the antrum. Diagnostic imaging did not reveal any metastatic lesion in liver. After a total gastrectomy, the patient's serum AFP level rapidly decreased, followed by a recurrence he developed of a carcinomatous pleuritis and death. On autopsy, an enlargement of the right testis was noticed for the first time. Histologically, it was found to be a malignant, non-epithelial tumor, which proved negative for anti-AFP staining by the ABC method and positive for anti *L-26. On the other hand, the gastric cancer was a poorly differentiated adenocarcinoma with a hepatoid differentiation which was positive for anti-AFP staining and negative for anti-L-26 so it thus was diagnosed as an AFP-producing gastric cancer.
 ...
PMID:[A case of AFP-producing gastric cancer accompanied with testicular tumor]. 246 35

This case concerns a 61-year-old man who had been determined as having rt-hypochondrialgia. The plasma AFP was found to have increased and an abdominal-CT revealed multiple low density areas in the liver. Endoscopic examination of the stomach revealed a Borrmann type III cancer and the specimens taken by punch biopsy demonstrated a tubular adenocarcinoma. Therefore, he had been diagnosed as having a gastric cancer with a metastatic liver cancer, or double cancer. Histologically, liver tumor proved to be a hepatocellular carcinoma (Edmondson: Gr III), and the histological findings of the gastric tumor was found to be identical with that of the liver tumor. The fact that this case has esophageal varices during the course of the disease suggested that metastasis to the stomach has likely occurred through the portal vein system.
 ...
PMID:[An autopsy revealing hepatocellular carcinoma with solitary metastatic gastric cancer]. 246

Serum levels of CA 125 and markers reputed as specific for cancers in relevant locations (squamous cell carcinoma, SCC, carcinoembryonic antigen, CEA, CA 19.9, alpha-fetoprotein, AFP) were determined in 107 patients with gastrointestinal (GI) carcinomas. The aim of this study was to assess their individual and combined sensitivities, and the power of CA 125 in excluding primary ovarian epithelial cancer from GI primary. Serum CA 125 levels (in U/ml) ranged from nondetectable to 400 in patients with esophageal, to 570 in those with gastric, and to 300 in patients with colorectal carcinoma. The levels for liver secondaries, pancreatic, and hepatocellular carcinoma were 480, 2,720 and 1,100 U/ml, respectively. Serum SCC antigen was elevated in all patients with esophageal cancer, CEA or CA 19.9 in 52% of patients with gastric cancer and in 63% with liver secondaries, and CEA in 95% of patients with colorectal cancer; whereas serum CA 125 above 65 U/ml was found in 25% of this subgroup, but only in those with already an elevated concentration of specific marker(s). Serum CEA or CA 19.9 was elevated in 71%, CA 125 in 59% of patients with pancreatic cancer; the latter mostly in those with already elevated CEA or CA 19.9. Serum AFP was elevated in 84% and CA 125 in 40% of patients with hepatoma; the latter mostly in those with already an elevated AFP. CA 125 values exceeding 1,000 U/ml were found in 1 patient with pancreatic cancer (2,720 U/ml) and in 2 with hepatoma (1,050 and 1,100 U/ml). These findings illustrate the nonspecificity of the CA 125 antigen, its small if any advantage compared to the specific markers, and they diminish its role as a marker for primary ovarian cancer from GI primary unless it exceeds 2,800 U/ml.
 ...
PMID:Serum levels of CA 125 in patients with gastrointestinal cancers. 248 Jun 31

A human gastric signet ring cancer cell line (Mz-Sto-1) was established in tissue culture from the ascites fluid of a 54-year-old patient. The tumor cells growing in tissue culture exhibit the morphological characteristics of signet ring cells in phase contrast and transmission electron microscopy. Mz-Sto-1 cells grow as monolayer with a population doubling time of 28-36 hr during exponential growth phase and show a chromosome number between 72 and 74. In the cellular DNA of Mz-Sto-1 cells no amplification of 19 oncogenes studied is observed, c-myc included. Mz-Sto-1 cells secrete 150-250 ng CEA per 10(7) cell in 3 days, but no AFP. In addition Mz-Sto-1 cells and 2 already established gastric cancer cell lines MKN-28 and MKN-45 express HLA- and blood group related antigens (A, Lewis). HLA-DR antigens, which are regularly detected on normal stomach epithelium, are not found on any of the 3 cultured gastric cell lines. Mz-Sto-1 cells represent the first human gastric cancer cell characterized ultrastructurally as signet ring cells. This line will be a valuable tool to study the biology and genetics of gastric carcinoma, to test cytostatic drugs and to define new antigenic markers for stomach cancer.
 ...
PMID:Signet ring stomach cancer: morphological characterization and antigenic profile of a newly established cell line (Mz-Sto-1). 282 Jul 43


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>